Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - Jama, 2020 - jamanetwork.com
Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …
被引用次数：308 相关文章

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes after Percutaneous Coronary Intervention: The …

NL Pereira, ME Farkouh, D So… - JAMA-Journal of …, 2020 - mayoclinic.pure.elsevier.com
Importance: After percutaneous coronary intervention (PCI), patients with CYP2C19* 2 or* 3
loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …
[PDF] selamedical.co.uk

[PDF][PDF] Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - JAMA, 2020 - selamedical.co.uk
OBJECTIVE To determine the effect of a genotype-guided oral P2Y12 inhibitor strategy on
ischemic outcomes in CYP2C19 LOF carriers after PCI. DESIGN, SETTING, AND …

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - 2020 - pubmed.ncbi.nlm.nih.gov
Importance After percutaneous coronary intervention (PCI), patients with CYP2C19* 2 or* 3
loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - JAMA, 2020 - europepmc.org
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel
Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI …

[引用][C] Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - JAMA, 2020 - cir.nii.ac.jp
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy
on Ischemic Outcomes After Percutaneous Coronary Intervention | CiNii Research CiNii 国立 …
[HTML] nih.gov

[HTML][HTML] Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - JAMA, 2020 - ncbi.nlm.nih.gov
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel
Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention - PMC Back to Top …

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes after Percutaneous Coronary Intervention: The …

NL Pereira, ME Farkouh, D So… - JAMA-Journal of …, 2020 - mayoclinic.elsevierpure.com
Importance: After percutaneous coronary intervention (PCI), patients with CYP2C19* 2 or* 3
loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - JAMA, 2020 - europepmc.org
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel
Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI …
[PDF] selamedical.co.uk

[PDF][PDF] Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary …

NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - JAMA, 2020 - selamedical.co.uk
OBJECTIVE To determine the effect of a genotype-guided oral P2Y12 inhibitor strategy on
ischemic outcomes in CYP2C19 LOF carriers after PCI. DESIGN, SETTING, AND …